BioStock: PolarCool sees potential in the US as competition grows

With the ambition to continue riding the wave of positive momentum, PolarCool recently raised 5 MSEK in a directed share issue to invest in further market expansion. As the company eyes the single largest market for medtech devices, the USA, competitor TecTraum’s pro2cool concussion treatment device recently received Breakthrough Device Designation from the FDA. BioStock got in touch with PolarCool’s CEO Erik Andersson to get his thoughts on the developments overseas and what it means for PolarCool’s ambitions.

Read the interview with Erik Andersson at biostock.se:

https://www.biostock.se/en/2021/12/polarcool-sees-potential-in-the-us-as-competition-grows/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se